Growth Metrics

Cellectis (CLLS) Gross Profit (2015 - 2023)

Cellectis (CLLS) posted Gross Profit of $627000.0 for Q4 2023, up 395.75% on a QoQ basis from -$212000.0 in Q3 2023, and up 1363.23% year-over-year from $42850.4 in Q4 2022.

Cellectis (CLLS) has 9 years of Gross Profit data on file, last reported at $627000.0 in Q4 2023.

  • In Q4 2023, Gross Profit rose 1363.23% year-over-year to $627000.0; the TTM figure through Dec 2023 stood at $343000.0 (down 83.74% YoY), while the FY2025 annual figure was $72.9 million, up 48.22% from the prior year.
  • Gross Profit climbed to $627000.0 in Q4 2023, from -$212000.0 in the prior quarter.
  • Across five years, Gross Profit topped out at $45.5 million in Q1 2020 and bottomed at -$5.0 million in Q4 2020.
  • A 5-year average of $2.9 million and a median of -$13465.9 in 2021 frame the typical range for Gross Profit.
  • Annual changes were most pronounced in 2019 — Gross Profit jumped 11034.21% — and 2020, when it sank 968.55%.
  • Year by year, Gross Profit stood at -$1.2 million in 2019, then slumped by 306.43% to -$5.0 million in 2020, then soared by 98.6% to -$69782.2 in 2021, then soared by 161.41% to $42850.4 in 2022, then jumped by 1363.23% to $627000.0 in 2023.
  • The last three Gross Profit figures came in at $627000.0 (Q4 2023), -$212000.0 (Q3 2023), and $123000.0 (Q2 2023), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 1,216,509.61 Bn 1,216,509.61 Bn -
2 Alterity Therapeutics 764,224.41 Bn 764,224.38 Bn -
3 Legend Biotech 2,716.00 Bn 2,715.71 Bn 242.10 Mn
4 Nanobiotix 2,248.83 Bn 2,248.77 Bn -
5 Akari Therapeutics 1,951.18 Bn 1,951.17 Bn -
6 Vertex Pharmaceuticals 113.69 Bn 106.44 Bn 2.59 Bn
7 Evaxion A 64.16 Bn 64.14 Bn -
8 Regeneron Pharmaceuticals 63.94 Bn 55.18 Bn 3.31 Bn
9 Alnylam Pharmaceuticals 40.13 Bn 37.12 Bn 959.66 Mn
10 Cellectis 20.83 Bn 20.62 Bn -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2023 116,000.00
Dec 31, 2023 116,000.00
Sep 30, 2023 -212,000.00
Sep 30, 2023 -212,000.00
Jun 30, 2023 123,000.00
Jun 30, 2023 123,000.00
Mar 31, 2023 -195,000.00
Mar 31, 2023 -195,000.00
Dec 31, 2022 42,850.39
Dec 31, 2022 42,850.39
Sep 30, 2022 -192,000.00
Sep 30, 2022 -192,000.00
Jun 30, 2022 978,000.00
Jun 30, 2022 978,000.00
Mar 31, 2022 1.28 Mn
Mar 31, 2022 1.28 Mn
Dec 31, 2021 -69,782.23
Dec 31, 2021 -69,782.23
Sep 30, 2021 -901,000.00
Sep 30, 2021 -901,000.00
Jun 30, 2021 -578,000.00
Jun 30, 2021 -578,000.00
Mar 31, 2021 17.46 Mn
Mar 31, 2021 17.46 Mn
Dec 31, 2020 -5.00 Mn
Dec 31, 2020 -5.00 Mn
Sep 30, 2020 -1.64 Mn
Sep 30, 2020 -1.64 Mn
Jun 30, 2020 -2.93 Mn
Jun 30, 2020 -2.93 Mn
Mar 31, 2020 45.53 Mn
Mar 31, 2020 45.53 Mn
Dec 31, 2019 -1.23 Mn
Dec 31, 2019 -1.23 Mn
Sep 30, 2019 4.23 Mn
Sep 30, 2019 4.23 Mn
Jun 30, 2019 337,000.00
Jun 30, 2019 337,000.00
Mar 31, 2019 450,000.00
Mar 31, 2019 450,000.00
Dec 31, 2018 248,000.00
Dec 31, 2018 248,000.00
Sep 30, 2018 38,000.00
Sep 30, 2018 38,000.00
Jun 30, 2018 4.49 Mn
Jun 30, 2018 4.49 Mn
Mar 31, 2018 5.46 Mn
Mar 31, 2018 5.46 Mn
Dec 31, 2017 6.03 Mn
Dec 31, 2017 6.03 Mn
Sep 30, 2017 5.55 Mn
Sep 30, 2017 5.55 Mn
Jun 30, 2017 208,914.37
Jun 30, 2017 208,914.37
Mar 31, 2017 6.13 Mn
Mar 31, 2017 6.13 Mn
Dec 31, 2016 7.58 Mn
Dec 31, 2016 7.58 Mn
Sep 30, 2016 10.92 Mn
Sep 30, 2016 10.92 Mn
Jun 30, 2016 345,741.76
Jun 30, 2016 345,741.76
Mar 31, 2016 7.22 Mn
Mar 31, 2016 7.22 Mn
Dec 31, 2015 34.75 Mn
Dec 31, 2015 34.75 Mn
Sep 30, 2015 8.08 Mn
Sep 30, 2015 8.08 Mn
Jun 30, 2015 7.67 Mn
Jun 30, 2015 7.67 Mn
Mar 31, 2015 9.04 Mn
Mar 31, 2015 9.04 Mn